Compare GSK plc (GSK) vs Lowe`s Companies Inc (LOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Lowe`s Companies Inc — how do they compare? GSK plc trades at $52.37 (market cap $101.34B), while Lowe`s Companies Inc trades at $214.32 (market cap $117.56B). The key difference: Lowe`s Companies Inc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | LOW | |
|---|---|---|
Market Cap | $101.34B | $117.56B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $287.39 |
52-Week Low | $36.20 | $206.62 |
Enterprise Value | $121.95B | $159.31B |
Dividend Yield | 3.49% | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Lowe's (LOW) trades at $207.71 with minimal daily movement, showing stable technical positioning near support at $207. The company maintains solid fundamentals with consistent earnings beats, a P/E of 17.72, and strong cash flow from operations of $9.63B in 2025. Recent dividend increases and a renewed partnership with Habitat for Humanity highlight ongoing corporate initiatives. Technical indicators show a mixed but leaning bearish signal overall, with oscillators suggesting potential near-term strength.
The outlook for Lowe's is cautiously optimistic, supported by analyst consensus favoring Buy ratings (60.79%) and a price target of $260.88. Key opportunities include margin stability and strategic growth in professional markets, while risks involve high debt levels and competitive pressures from Home Depot. Investors should weigh strong cash generation against macroeconomic sensitivity in the home improvement sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →
